Shares of biotech innovator Momenta Pharmaceuticals (NASDAQ:MNTA) entered into a nosedive in early June, but quickly recovered after analysts at UBS AG upgraded the stock from "neutral" to "buy." I don't put any faith in analyst projections -- and neither should you -- but I do see value in the company's technology. Momenta has developed a platform for analyzing and characterizing complex molecules that could significantly reduce R&D costs and development times of drugs in the pipeline. If you're an investor looking for a biotech company with boatloads of potential, you may be wondering about adding Momenta to your portfolio. Fool contributor Maxx Chatsko breaks down that decision for investors in the following video.

Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.

The Motley Fool recommends Momenta Pharmaceuticals. The Motley Fool owns shares of Momenta Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.